Literature DB >> 17593517

Mesangial proliferative glomerulonephritis with aldosterone-producing adenoma.

Masayuki Tanemoto1, Michiaki Abe2, Fumitoshi Satoh2, Takaaki Abe2, Hiroshi Satoh2, Sadayoshi Ito2.   

Abstract

We describe a case of mesangial proliferative glomerulonephritis (MesPGN), the clinical symptoms of which were exacerbated by aldosterone-producing adenoma (APA). A 45-year-old man, who had had a history of hypertension for several years, presented with renal derangement, with serum creatinine at its upper normal limit and with microhematuria and proteinuria. He also presented with hypokalemia, with a plasma aldosterone concentration at its upper normal limit and plasma renin activity at its lower normal limit. After the administration of spironolactone, we resected his left adrenal gland, which had a nodular lesion as well as aldosterone hypersecretion. The treatment normalized his arterial blood pressure and serum potassium concentration. Although his proteinuria disappeared with the reduction in arterial blood pressure, the microhematuria continued. The administration of losartan because of the histological finding of MesPGN reduced the amount of hematuria. A dissociated response of hematuria and proteinuria to antihypertensive treatment indicated that MesPGN was coincidental with APA.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17593517     DOI: 10.1007/s10157-007-0460-0

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  25 in total

1.  A study of the adrenal status in hypertension.

Authors:  A H SHAMMA; J W GODDARD; S C SOMMERS
Journal:  J Chronic Dis       Date:  1958-11

2.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors: 
Journal:  JAMA       Date:  2002-12-18       Impact factor: 56.272

3.  Nationwide and long-term survey of primary glomerulonephritis in Japan as observed in 1,850 biopsied cases. Research Group on Progressive Chronic Renal Disease.

Authors: 
Journal:  Nephron       Date:  1999       Impact factor: 2.847

4.  The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Authors:  H H Parving; H Lehnert; J Bröchner-Mortensen; R Gomis; S Andersen; P Arner
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

5.  Tissue-specific expression of renin-angiotensin system components in IgA nephropathy.

Authors:  Chie Miyake-Ogawa; Masanobu Miyazaki; Katsushige Abe; Takashi Harada; Yoshiyuki Ozono; Hideto Sakai; Takehiko Koji; Shigeru Kohno
Journal:  Am J Nephrol       Date:  2005-01-07       Impact factor: 3.754

6.  The prevalence of secondary and curable hypertension.

Authors:  M Danielson; B Dammström
Journal:  Acta Med Scand       Date:  1981

7.  The Italian experience of the national registry of renal biopsies.

Authors:  Loreto Gesualdo; Anna Maria Di Palma; Luigi Francesco Morrone; Giovanni Fabrizio Strippoli; Francesco Paolo Schena
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

8.  Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.

Authors:  H E Montgomery; L A Kiernan; C E Whitworth; S Fleming; T Unger; P Gohlke; J J Mullins; J R McEwan
Journal:  J Hypertens       Date:  1998-05       Impact factor: 4.844

9.  Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial.

Authors:  Manuel Praga; Eduardo Gutiérrez; Ester González; Enrique Morales; Eduardo Hernández
Journal:  J Am Soc Nephrol       Date:  2003-06       Impact factor: 10.121

10.  Secondary hypertension in a blood pressure clinic.

Authors:  A M Sinclair; C G Isles; I Brown; H Cameron; G D Murray; J W Robertson
Journal:  Arch Intern Med       Date:  1987-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.